Owen Mumford Announces Verified Science-based Targets & Plans for Net zero

Owen Mumford, a global leader in the design, manufacture and advancement of medical devices, has announced its emissions reduction targets through the Science Based Targets initiative (SBTi). The company has set a target to achieve net zero by 2045 (to mirror the UK NHS target) in alignment with the recommendations of the 2015 Paris Agreement.

Using science-based targets, companies can determine how much and how quickly they need to reduce their greenhouse gas (GHG) emissions to prevent the worst effects of climate change. The Science Based Targets initiative (SBTi) sets science-based emissions reduction targets in line with climate science, supporting companies as they mobilise ambitious climate action efforts in the private sector. Over 2,000 companies worldwide have already set their targets.

As part of its sustainability action plan, the company has joined the Business Ambition for 1.5°c commitment and is one of the first 1000 global businesses to sign up. Launched in 2019, the initiative asks members to pledge to achieve net zero emissions by the latest 2050 following the United Nations Intergovernmental Panel on Climate Change (IPCC) warning that an increase of 1.5°c in global temperature will have catastrophic effects.

By joining the commitment, Owen Mumford also joins the Race to Zero movement, a collaborative effort of leaders across the globe supporting efforts to achieve zero carbon recovery. Owen Mumford recently became one of the first medical device manufacturers in the world to achieve B Corp certification following the establishment of its sustainability programme in 2014 and formal commitment to the United Nation’s Sustainable Development Goals (SDGs). To formalise the pledge to reduce the environmental impact of its operations, Owen Mumford has now set a science-based target, with its base year as 2015. The company will establish a pathway in 2022, including milestones to mark the achievement of goals and measure its success. The focus will be on Scope 3 emissions, which covers factors such as purchased goods and services, business travel and waste disposal.

Jarl Severn, Ceo At Owen Mumford
Jarl Severn, CEO at Owen Mumford

Jarl Severn, CEO at Owen Mumford said: “Owen Mumford has been an innovator of medical devices for decades, and we understand the importance of leading by example when it comes to the environment and our impact as a business. Setting a science-based target with the SBTi will hold us accountable and help us to reach our net zero target for 2045. We hope this commitment will inspire other businesses to implement their own sustainability targets and work towards the goal of a carbon neutral future.”

Hot this week

Voluntary Recall Notifying Medtronic Insulin Pump Users of Potential Risks of Shortened Pump Battery Life

Medtronic plc voluntarily issued a field action starting on July 31, 2024, notifying global customers of its MiniMed™ 600 series or 700 series insulin pumps to follow their pump's built-in alerts and alarms for battery status and to contact Medtronic if they observe changes in the battery life of their pump

Medtronic Expands AiBLE Spine Surgery Ecosystem with New Technologies and Siemens Healthineers Partnership

New advancements in the AiBLE Spine Surgery ecosystem build upon the company's commitment to procedural innovation and execution

Axlab, Danish Medtech Pioneer, expands to US with Advanced Robotic Tissue Sectioning for Pathology Laboratories

Kris Rokke, National Sales Director for Axlab in the US. "My team and I are extremely excited and honored about this unique opportunity to also offer this advanced technology to labs across the US and thus contribute to the pathology labs of tomorrow."

Spartan Medical Broadens Single-Use Sterile Instrument Portfolio to Improve Outcomes, Increase Efficiency, and Generate Cost Savings

Spartan Medical products portfolio of single-use, sterile med tech includes micro and minor surgical convenience kits, kerrison rongeurs, spinal and general surgical retractors, dural repair kits, synthetic biologics, and a wide range of orthopedic pre-sterilized implants and devices.

Recor Medical Supports European Society of Cardiology’s Hypertension Guidelines

Record Medical notes the new guidelines, "2024 ESC Guidelines for the management of elevated blood pressure and hypertension," have been published online and recommend the consideration of renal denervation (RDN) as a safe and effective treatment option for patients who have uncontrolled resistant hypertension or those that have uncontrolled hypertension with a higher risk of cardiovascular disease, who express a preference to undergo RDN.